These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 26505682)

  • 1. The anti-tuberculosis agents under development and the challenges ahead.
    Kumar D; Negi B; Rawat DS
    Future Med Chem; 2015; 7(15):1981-2003. PubMed ID: 26505682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tuberculosis: the drug development pipeline at a glance.
    Villemagne B; Crauste C; Flipo M; Baulard AR; Déprez B; Willand N
    Eur J Med Chem; 2012 May; 51():1-16. PubMed ID: 22421275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tackling Drug-Resistant Tuberculosis: Current Trends and Approaches.
    Tandon R; Nath M
    Mini Rev Med Chem; 2017; 17(6):549-570. PubMed ID: 27280980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Present and future in the use of anti-tubercular drugs].
    Didilescu C; Craiova UM
    Pneumologia; 2011; 60(4):198-201. PubMed ID: 22420168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimycobacterial drugs currently in Phase II clinical trials and preclinical phase for tuberculosis treatment.
    Engohang-Ndong J
    Expert Opin Investig Drugs; 2012 Dec; 21(12):1789-800. PubMed ID: 22991970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in the research of heterocyclic compounds as antitubercular agents.
    Yan M; Ma S
    ChemMedChem; 2012 Dec; 7(12):2063-75. PubMed ID: 23042656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drugs in development for tuberculosis.
    Ginsberg AM
    Drugs; 2010 Dec; 70(17):2201-14. PubMed ID: 21080738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.
    Poce G; Cocozza M; Consalvi S; Biava M
    Eur J Med Chem; 2014 Oct; 86():335-51. PubMed ID: 25173852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel compounds and drugs and recent patents in treating multidrug-resistant and extensively drug-resistant tuberculosis.
    Cheepsattayakorn A; Cheepsattayakorn R
    Recent Pat Antiinfect Drug Discov; 2012 Aug; 7(2):141-56. PubMed ID: 22670838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tuberculosis: clinical trials and new drug regimens.
    Kwon YS; Jeong BH; Koh WJ
    Curr Opin Pulm Med; 2014 May; 20(3):280-6. PubMed ID: 24614239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New drugs for tuberculosis treatment.
    Sánchez F; López Colomés JL; Villarino E; Grosset J
    Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 1():47-56. PubMed ID: 21420567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New drugs for the treatment of tuberculosis: hope and reality.
    Grosset JH; Singer TG; Bishai WR
    Int J Tuberc Lung Dis; 2012 Aug; 16(8):1005-14. PubMed ID: 22762423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents.
    Pieroni M; Wan B; Cho S; Franzblau SG; Costantino G
    Eur J Med Chem; 2014 Jan; 72():26-34. PubMed ID: 24333612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent progress in the drug development of coumarin derivatives as potent antituberculosis agents.
    Keri RS; Sasidhar BS; Nagaraja BM; Santos MA
    Eur J Med Chem; 2015 Jul; 100():257-69. PubMed ID: 26112067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New antituberculous drugs in development.
    Lalloo UG; Ambaram A
    Curr HIV/AIDS Rep; 2010 Aug; 7(3):143-51. PubMed ID: 20559756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New anti-tuberculosis drugs in clinical trials with novel mechanisms of action.
    Rivers EC; Mancera RL
    Drug Discov Today; 2008 Dec; 13(23-24):1090-8. PubMed ID: 18840542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances of pyrazole-containing derivatives as anti-tubercular agents.
    Xu Z; Gao C; Ren QC; Song XF; Feng LS; Lv ZS
    Eur J Med Chem; 2017 Oct; 139():429-440. PubMed ID: 28818767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developments in chemical approaches to treat tuberculosis in the last decade.
    Tripathi RP; Bisht SS; Ajay A; Sharma A; Misra M; Gupt MP
    Curr Med Chem; 2012; 19(4):488-517. PubMed ID: 22204345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of moxifloxacin and linezolid against Mycobacterium tuberculosis in combination with potentiator drugs verapamil, timcodar, colistin and SQ109.
    de Knegt GJ; van der Meijden A; de Vogel CP; Aarnoutse RE; de Steenwinkel JE
    Int J Antimicrob Agents; 2017 Mar; 49(3):302-307. PubMed ID: 28162983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.